PTEN mutation	Prostate Cancer	PTEN mutation	Prostate Cancer	enzalutamide + CC-115 Sensitive: C3 – Early Trials enzalutamide + CC-115 Sensitive : C3	enzalutamide + CC-115 Sensitive: C3 – Early Trials enzalutamide + CC-115 Sensitive : C3
PTEN deletion	Prostate Cancer	PTEN deletion	Prostate Cancer	enzalutamide + CC-115 Sensitive: C3 – Early Trials enzalutamide + CC-115 Sensitive : C3	enzalutamide + CC-115 Sensitive: C3 – Early Trials enzalutamide + CC-115 Sensitive : C3
High MHC-II signature	Bladder Cancer	High MHC-II signature	Bladder Cancer	NU7441 Sensitive: C3 – Early Trials NU7441 Sensitive : C3	NU7441 Sensitive: C3 – Early Trials NU7441 Sensitive : C3
ATM deletion	Squamous Cell Carcinoma of Head and Neck	ATM deletion	Squamous Cell Carcinoma of Head and Neck	olaparib + AZD7648 Sensitive: D – Preclinical olaparib + AZD7648 Sensitive : D	olaparib + AZD7648 Sensitive: D – Preclinical olaparib + AZD7648 Sensitive : D
NPM-RARA fusion	Acute Myelogenous Leukemia	NPM-RARA fusion	Acute Myelogenous Leukemia	M3814 Sensitive: D – Preclinical M3814 Sensitive : D	M3814 Sensitive: D – Preclinical M3814 Sensitive : D
BRCA deletion	Ovarian Cancer	BRCA deletion	Ovarian Cancer	olaparib + AZD7648 Sensitive: D – Preclinical olaparib + AZD7648 Sensitive : D	olaparib + AZD7648 Sensitive: D – Preclinical olaparib + AZD7648 Sensitive : D
PIK3CA mutation	Non Small Cell Lung Cancer	PIK3CA mutation	Non Small Cell Lung Cancer	CC-115 Sensitive: D – Preclinical CC-115 Sensitive : D	CC-115 Sensitive: D – Preclinical CC-115 Sensitive : D
TP53 mutation	Solid Tumor	TP53 mutation	Solid Tumor	M3814 + VP-006 Sensitive: D – Preclinical M3814 + VP-006 Sensitive : D	M3814 + VP-006 Sensitive: D – Preclinical M3814 + VP-006 Sensitive : D
MYC expression + MCL1 expression	Diffuse Large B Cell Lymphoma	MYC expression + MCL1 expression	Diffuse Large B Cell Lymphoma	venetoclax + BR101801 Sensitive: D – Preclinical venetoclax + BR101801 Sensitive : D	venetoclax + BR101801 Sensitive: D – Preclinical venetoclax + BR101801 Sensitive : D
ATM deletion	Bladder Cancer	ATM deletion	Bladder Cancer	M3814 Sensitive: D – Preclinical M3814 Sensitive : D	M3814 Sensitive: D – Preclinical M3814 Sensitive : D

DNA PK inhibitor

DNA PK inhibitor

Associations(10)

Associations
(10)